Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). - Wikidata - wikimedia - TriplyDB

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

http://www.wikidata.org/entity/Q34587610

about

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis Regulation of brown adipose tissue recruitment, metabolism and thermogenic function by peroxisome proliferator-activated receptor γ Drugs for type 2 diabetes: role in the regulation of bone metabolism Nuclear receptors in bone physiology and diseases Bone: incretin hormones perceiver or receiver?The alliance of mesenchymal stem cells, bone, and diabetes On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles 5-Androstene-3β,7β,17β-triol (β-AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosis Diabetes, bone and glucose-lowering agents: clinical outcomes.PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.The current role of thiazolidinediones in diabetes management.Calcific aortic valve stenosis: methods, models, and mechanisms Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span Obesity, Type 2 Diabetes and Bone in Adults.Optimal therapy of type 2 diabetes: a controversial challenge Thiazolidinediones and bone fractures.Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action.Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.Fractures are increased and bisphosphonate use decreased in individuals with insulin-dependent diabetes: a 10 year cohort study Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.Control of macrophage activation and function by PPARs.Disease burden evaluation of fall-related events in the elderly due to hypoglycemia and other diabetic complications: a clinical review.Cultured human periosteal-derived cells have inducible adipogenic activity and can also differentiate into osteoblasts in a perioxisome proliferator-activated receptor-mediated fashion.Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.Pharmacogenetics of Anti-Diabetes Drugs.The Look AHEAD Trial: bone loss at 4-year follow-up in type 2 diabetes.A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity Fat infiltration of muscle, diabetes, and clinical fracture risk in older adults.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Medication-induced osteoporosis: screening and treatment strategies Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Thiazolidinediones and fractures: evidence from translating research into action for diabetes.Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.Fracture risk in diabetic elderly men: the MrOS study.Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation Cellular and molecular effects of thiazolidinediones on bone cells: a review.Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

P2860

Q22241134-1006EBAF-DA40-472C-ADB0-EC1FF7F87BEF Q24655666-44ED723B-AFD2-4F7E-B28C-91F3B4F169BD Q26745781-4F87B375-9A69-46D9-899F-6B2CAD04E32D Q26775763-0A5CF49C-D7BE-4F43-A4D8-D2EFCAA9F957 Q26853017-86504FE2-0349-408A-88A0-86B611CBB95D Q27008949-93BE7698-D23B-4D51-A861-9BA86504A162 Q27012497-AC57E036-F85F-4103-8852-686B5117B061 Q27697692-D63A9C94-6F49-4527-8BCB-B37B592CE666 Q28748762-9E7C683A-C4D6-4A99-AD1D-09B8A855C124 Q30234622-D2680088-CB4A-48C7-A662-1BDF29C4D6A3 Q30241952-131006ED-7AA2-47BB-8BF5-CF22347192E2 Q30250347-979F89F4-EFC4-4B20-9D3F-E0ED739339AA Q30503246-D5CF8605-371C-493F-8500-8214B6819FD8 Q30572405-143AB84E-1F10-4C98-A679-7C2111B57E8E Q33571597-56387B18-96CF-4F1B-BE3E-B884AEBF7066 Q33577712-D01AD82B-D730-48D4-BD3B-6A0C9DDD59DC Q33603516-0CE6A348-7B0A-4D5F-9C52-C0BBC82CB5D0 Q33717450-CE453F25-A679-4035-9208-5A00B41831B9 Q33736122-5C5D8E0C-45CA-41DC-9A19-070E260EE64A Q33772312-98BC10D2-022F-479B-B791-172E33C6DF47 Q33785248-DC3EF016-BE07-4793-8220-32F08266C6B5 Q33960879-3E5A7E86-20F7-41BD-B303-73AA99951844 Q33962601-B7AB95FC-5E60-4047-9209-E2093568B711 Q34073775-E5743849-2BC4-4D00-AE1D-6E058534E332 Q34102038-474EEA4C-B1FE-49C3-B55C-5364AF8BB502 Q34161200-A277B436-76B0-47AF-BFCF-BC3456AC4047 Q34181995-0B634CF6-6D68-4953-A34D-A686AAFFDEEC Q34219386-99A9CEA8-6F75-44CE-97D5-F59D914C0248 Q34249161-9814B56B-D204-4EC5-84DE-1CEC9E381FE5 Q34262418-D9A2D6A1-6E30-4B53-BE78-A28A9D1E9179 Q34315432-8FC4EF28-CD42-4657-BA50-C3E320D244ED Q34389358-FE32D8B4-B997-4D15-B052-BBDD4FCD92F0 Q34563587-2403BDB1-0344-48E8-9750-E5541DC4539B Q34630672-C5C7A087-C200-4F09-A0E0-52773487A671 Q34636672-CFA36E24-6934-4AE2-B04A-14840EC7D85E Q34888374-637447A2-D4BA-4968-8E75-8998489F07A3 Q35130554-3CBA0186-255C-4DEF-9E7C-165C284EFA0E Q35230678-4A2193DB-B7DC-4CE0-902C-069DA9D76250 Q35346767-1780983F-2142-4492-90FB-5BA0CB4FB030 Q35408148-7D93D2FE-5275-4F6E-B758-EFCA202390F8

P2860

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

http://www.wikidata.org/entity/Q34587610

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).

@ast

Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).

@en

Rosiglitazone-associated fract ...... etes Outcome Progression Trial

@nl

type

label

Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).

@ast

Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).

@en

Rosiglitazone-associated fract ...... etes Outcome Progression Trial

@nl

prefLabel

Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).

@ast

Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).

@en

Rosiglitazone-associated fract ...... etes Outcome Progression Trial

@nl

P1433

Q34587610-38ED8ADA-4CE3-4184-956C-EAB4D39EB4B7

P1476

Q34587610-CFDE7E63-7D4B-47FC-B1E6-AD1255DE6FED

P2093

Q34587610-1676F53A-D35D-4188-BAD9-FBD78530C742

Q34587610-2498161F-0073-4E41-945B-C45C028234A9

Q34587610-73656E0A-2F57-4293-9232-6F9A7A0F31FB

Q34587610-73EEF454-7204-4F73-93B9-7270A8CA80B6

Q34587610-7446BFC6-53C6-4309-9089-0BFFF6A53117

Q34587610-7C1DEBF4-DF13-46E0-9166-D993ADD74A55

Q34587610-9F806D9E-D488-41C1-9AB4-07697179140B

Q34587610-B52D8991-4C9C-4E35-B090-1BAF6403D26C

Q34587610-ED4FD281-F966-4AA8-9FE6-B78B34506638

P304

Q34587610-4400A133-5D88-4502-96CE-E916CBF32402

P31

Q34587610-BE621699-D5C6-48D4-B577-8792C7942F1D

P356

Q34587610-F13EFF90-4455-43B1-B7FF-95D5CE0A7F6B

P407

Q34587610-95096105-09AF-4B42-8B05-E080D762EB11

P433

Q34587610-29C748E0-B022-4365-911E-002DAA478D30

P478

Q34587610-07EAD66E-844E-4490-9ACC-2B3DCEA9D4D9

P50

Q34587610-75C106D6-84B4-4530-8D2B-DCB70FE08139

Q34587610-7602CEC1-CDF8-474B-A353-48D524D2A097

Q34587610-C23AC29A-CA36-4C1F-AA12-38E7DC187546

P577

Q34587610-B17FB0BA-A410-4F99-814B-0E3B68256C21

P5875

Q34587610-8FC42E87-9A58-417C-89BB-2291FDC364DB

P698

Q34587610-57547FBD-6B78-46C7-ADC4-9DB0F9177D0C

P921

Q34587610-BFE26454-BDB6-47DE-AD71-B51A6BCB9423

P356

P1433

P1476

Rosiglitazone-associated fract ...... ome Progression Trial (ADOPT).

@en

P2093

Barbara G Kravitz

http://www.w3.org/2001/XMLSchema#string

Dahong Yu

http://www.w3.org/2001/XMLSchema#string

Diabetes Outcome Progression Trial (ADOPT) Study Group

http://www.w3.org/2001/XMLSchema#string

Giancarlo Viberti

http://www.w3.org/2001/XMLSchema#string

Mark A Heise

http://www.w3.org/2001/XMLSchema#string

R Paul Aftring

http://www.w3.org/2001/XMLSchema#string

Rury R Holman

http://www.w3.org/2001/XMLSchema#string

Steven M Haffner

http://www.w3.org/2001/XMLSchema#string

William H Herman

http://www.w3.org/2001/XMLSchema#string

P304

845-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC07-2270

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5628862

http://www.w3.org/2001/XMLSchema#string

P698

18223031

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes